Table 4.
Treatment options in PsA
| Type of Treatment | Name | Comments |
|---|---|---|
| Non-pharmacologic therapies[36] | Physical exercise Diet adjustment Occupational therapy Cessation of smoking |
Help improvement treatment outcome; not enough on their own. |
| NSAIDs[37] | Naproxen Ibuprofen |
First line in mild-to-moderate disease. Relieves symptoms but does not stop progression of disease. |
| DMARDs[37] | Methotrexate Leflunomide Sulfasalazine |
Older drugs, no longer preferred as first-line. Can decrease or reverse disease progression. |
| Biologicals[35] (preferred over DMARDs now): | ||
| TNF-alpha inhibitors | Infliximab Adalimumab Etanercept |
First-line, more effective. |
| IL-17 inhibitors | Seckinumab Ixekizumab |
Choice after TNF alpha inhibitors |
| IL 12/23 inhibitor | Ustekinumab | |
| IL 23 inhibitor | Guselkumab | |
| T-cell co stimulator | Abatacept | |
| JAK inhibitor | Tofacitinib | Newly introduced |
| PDE4 inhibitor | Apremilast | Newly introduced, may be used first-line. |
PsA=psoriatic arthritis, NSAIDs=non-steroidal anti-inflammatory drugs, DMARDs=conventional Disease modifying anti-rheumatic drugs, TNF= Tumour necrosis factor, JAK= Janus kinase, PDE4= Phosphodiesterase 4, IL= Interleukin